<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099187</url>
  </required_header>
  <id_info>
    <org_study_id>MA39189</org_study_id>
    <secondary_id>2016-002744-17</secondary_id>
    <nct_id>NCT03099187</nct_id>
  </id_info>
  <brief_title>A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease</brief_title>
  <official_title>Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pirfenidone in&#xD;
      participants with fibrosing interstitial lung disease (ILD) who cannot be classified with&#xD;
      moderate or high confidence into any other category of fibrosing ILD by multidisciplinary&#xD;
      team (MDT) review (&quot;unclassifiable&quot; ILD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be randomised to receive 801 mg pirfenidone or placebo three times&#xD;
      daily for 24 weeks. The efficacy of pirfenidone versus placebo will be assessed by daily&#xD;
      measurement of forced vital capacity using a handheld spirometer over the treatment period.&#xD;
      Additionally, the study will assess the efficacy and safety of pirfenidone with and without&#xD;
      concomitant mycophenolate mofetil treatment and in study participants with or without&#xD;
      interstitial pneumonia with autoimmune features (IPAF). All study participants who attend the&#xD;
      follow-up visit at Week 28 will be offered the opportunity to receive open-label pirfenidone&#xD;
      within the trial protocol. In order to maintain blinding of the controlled period of the&#xD;
      study, all study participants will discontinue treatment by Week 24 and return for a&#xD;
      follow-up visit 4 weeks later. Study participants eligible to participate in the single-arm&#xD;
      12-month extension will be initiated on open-label pirfenidone during this visit (re-starting&#xD;
      the dose titration from one capsule three times daily [TID]). During the long-term extension&#xD;
      period, study participants will be monitored for safety, initially at monthly visits during&#xD;
      the first 6 months and thereafter approximately every 3 months. A final follow-up visit will&#xD;
      take place 4 weeks after the last dose of pirfenidone is taken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">November 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted FVC</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in FVC of &gt;5%</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in FVC of &gt;10%</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute Walk Distance (6MWD)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Comparison of 6-minute walk distance before beginning and after completing study therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in University of California, San Diego-Shortness of Breath Questionnaire Score</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score in Leicester Cough Questionnaire Score</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cough Visual Analog Scale (VAS) Score</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-elective Hospitalization, Both Respiratory and All Cause</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Participants with non-elective hospitalization are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Investigator-reported Acute Exacerbations</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Percentage of participants with acute exacerbation arereported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Investigator-reported Acute Exacerbations</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Time to first investigator reported acute exacerbations from start of treatment are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, a &gt;50 m decline of 6MWD, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>PFS is defined as the time to the first occurrence of a &gt;10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death From Any Cause</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Time to first documented death from start of treatment is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death From Respiratory Diseases</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Time to first documented death due to respiratory diseases from start of treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline (Day 1) to Week 28</time_frame>
    <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period</measure>
    <time_frame>From administration of the first dose of study drug to Week 24</time_frame>
    <description>Number of participants with dose reduction and treatment interruptions are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up</measure>
    <time_frame>From the Follow-up Visit at Week 28 through the follow-up period of 12 Months</time_frame>
    <description>Number of participants with dose reduction and treatment interruptions are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Number of participants withdrawn from trial treatment or trial discontinuations are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up</measure>
    <time_frame>From the Follow-up Visit at Week 28 through the follow-up period of 12 Months</time_frame>
    <description>Number of participants withdrawn from trial treatment or trial discontinuations are reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone 267 mg capsules three times in a day.</description>
    <arm_group_label>Pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules three times in a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18-85 years&#xD;
&#xD;
          -  Confirmed fibrosing ILD which, following multidisciplinary team review, cannot be&#xD;
             classified with either high or moderate confidence as a specific idiopathic&#xD;
             interstitial pneumonia or other defined ILD&#xD;
&#xD;
          -  Progressive disease as considered by the investigator as participants deterioration&#xD;
             within the last 6 months, which is defined as a rate of decline in forced vital&#xD;
             capacity (FVC) &gt;5% or a significant symptomatic worsening not due to cardiac,&#xD;
             pulmonary vascular or other causes&#xD;
&#xD;
          -  Extent of fibrosis &gt;10% on high-resolution computed tomography&#xD;
&#xD;
          -  Forced vital capacity &gt;= 45% of predicted value&#xD;
&#xD;
          -  Diffusing capacity of the lung for carbon monoxide (DLco) &gt;= 30% of predicted value&#xD;
&#xD;
          -  Forced expiratory volume in 1 second/FVC ratio &gt;= 0.7&#xD;
&#xD;
          -  Able to do 6-minute walk distance (6MWD) &gt;= 150 meters&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent or use a&#xD;
             non-hormonal or hormonal contraceptive method with a failure rate of &lt; 1% per year&#xD;
             during the treatment period and for at least 90 days after the last dose of&#xD;
             pirfenidone&#xD;
&#xD;
          -  For men, agreement to remain abstinent or use contraceptive measures, and agreement to&#xD;
             refrain from donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis with moderate or high confidence of nonspecific interstitial pneumonia and&#xD;
             any ILD with an identifiable cause such as connective tissue disease-ILD, chronic&#xD;
             hypersensitivity pneumonitis, or others&#xD;
&#xD;
          -  Diagnosis of idiopathic pulmonary fibrosis independent of the confidence level&#xD;
&#xD;
          -  History of unstable angina or myocardial infarction during the previous 6 months&#xD;
&#xD;
          -  Treatment with high dose systemic corticosteroids, or any immunosuppressant other than&#xD;
             mycophenolate mofetil/acid (MMF), at any time within the 4 weeks of the screening&#xD;
             period. Participants being treated with MMF should be on a stable dose that is&#xD;
             expected to remain stable throughout the trial and was started at least 3 months prior&#xD;
             to screening&#xD;
&#xD;
          -  Participants previously treated with pirfenidone or nintedanib&#xD;
&#xD;
          -  Participants treated with N-acetyl-cysteine for fibrotic lung disease, at any time&#xD;
             within the 4 weeks of the screening period&#xD;
&#xD;
          -  Drug treatment for any type of pulmonary hypertension&#xD;
&#xD;
          -  Participation in a trial of an investigational medicinal product within the last 4&#xD;
             weeks&#xD;
&#xD;
          -  Significant other organ co-morbidity including hepatic or renal impairment&#xD;
&#xD;
          -  Predicted life expectancy &lt; 12 months or on an active transplant waiting list&#xD;
&#xD;
          -  Use of any tobacco product in the 12 weeks prior to the start of screening, or any&#xD;
             unwillingness to abstain from their use through to the Follow-up Visit&#xD;
&#xD;
          -  Illicit drug or alcohol abuse within 12 months prior to screening&#xD;
&#xD;
          -  Planned major surgery during the trial&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients of pirfenidone&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Concomitant use of fluvoxamine&#xD;
&#xD;
          -  Clinical evidence of any active infection&#xD;
&#xD;
          -  Any history of hepatic impairment, elevation of transaminase enzymes, or liver&#xD;
             function test results as: Total bilirubin above the upper limit of normal (ULN),&#xD;
             Aspartate aminotransferase or alanine aminotransferase &gt;1.5 × ULN, and Alkaline&#xD;
             phosphatase &gt;2.0 × ULN&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 milliliter (mL) per minute, calculated using the&#xD;
             Cockcroft-Gault formula&#xD;
&#xD;
          -  Any serious medical condition, clinically significant abnormality on an&#xD;
             Electrocardiogram (ECG) at screening, or laboratory test results&#xD;
&#xD;
          -  An ECG with a heart rate corrected QT interval using Fridericia's formula as &gt;= 500&#xD;
             milliseconds at screening, or a family or personal history of long QT syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital; Respiratory Department; Respiratory Department</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Research Queensland</name>
      <address>
        <city>Nundah</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital; Respiratory Clinical Trials Unit, Thoracic Medicine</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Department</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahan</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital; Advanced Lung Disease Unit</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacifica Lung Research Center/St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno-Bohunice; Klinika Tuberkulozy A Respiracnich Chorob</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc; Pneumologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital; Lungesygdomme, Forskning</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital, Lungemedicinsk Afdeling</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Lungemedicinsk Afdeling J</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH; Pneumologie</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evang. Lungenklinik Berlin Klinik für Pneumologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Justus-Liebig-Universität; Innere Medizin</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens &quot;Attikon&quot;, B' University Pulmonary Clinic</name>
      <address>
        <city>Chaidari</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklio, Pulmonary Clinic</name>
      <address>
        <city>Heraklio</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka; Pulmonary Clinic</name>
      <address>
        <city>Beer Sheba</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center; Pulmonary Institute</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center; Pulmonary Inst.</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center; Pulmonary Institute</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Pulmonary Dept</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Center; Pulmonary Inst.</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni-Pierantoni; U.O. Pneumologia</name>
      <address>
        <city>Forlì</city>
        <state>Emilia-Romagna</state>
        <zip>47121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe; U.O. di Pneumologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Ospedali Riuniti Umberto I -G.M. Lancisi-G. Salesi Ancona; SOD Pneumologia</name>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Marche</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria San Luigi Gonzaga di Orbassano; Ambulatorio per le Malattie Rare del Polmone</name>
      <address>
        <city>Orbassano (TO)</city>
        <state>Piemonte</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi; SOD Pneumologia e Fisiopatologia Toracico Polmonare</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne;Klinika Alergologii i Pneumonologii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Nr 1 im.N.Barlickiego Oddzial Kliniczny Pneumonologii i Alergologii</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infante D. Pedro; Servico de Pneumologia</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUC; Servico de Pneumologia A</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao; Servico de Pneumologia</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHVNG/E_Unidade 1; Servico de Pneumologia</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge ; Servicio de Neumologia</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08097</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de neumologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa; Servicio de Neumologia</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos - Servicio de Neumologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Neumologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B17 0NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital; Respiratory Department</name>
      <address>
        <city>Bristol</city>
        <zip>BS10-5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust; Respiratory Department</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary; Respiratory Department</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital (Wonford)</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital; Respiratory Medicine</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital; Respiratory Department</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital; North West Lung Research Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>November 14, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2020</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03099187/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03099187/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pirfenidone</title>
          <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
        </group>
        <group group_id="P3">
          <title>Open-Label Treatment (Pirfenidone)</title>
          <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
        </group>
        <group group_id="P4">
          <title>Open-Label Treatment (Placebo)</title>
          <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lung transplantation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with Protocol procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-month Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lung transplantation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptomatic deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pirfenidone</title>
          <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24. After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24. After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="253"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="10.1"/>
                    <measurement group_id="B2" value="67.7" spread="9.2"/>
                    <measurement group_id="B3" value="67.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period</title>
        <description>Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.</description>
        <time_frame>Up to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period</title>
          <description>Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Analysis in 2019</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" lower_limit="-311.7" upper_limit="275.9"/>
                    <measurement group_id="O2" value="116.6" lower_limit="-451.9" upper_limit="685.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Analysis in 2020</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.3" lower_limit="-157.0" upper_limit="-23.7"/>
                    <measurement group_id="O2" value="125.6" lower_limit="-458.4" upper_limit="709.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019. Mean FVC decline comparison between treatment groups using a Student's t-test with a two-sided significance level of 0.05</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6777</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and is provided for descriptive purpose only</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Group Means</param_type>
            <param_value>-134.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-772.4</ci_lower_limit>
            <ci_upper_limit>503.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020. Mean FVC decline comparison between treatment groups using a Student's t-test with a two-sided significance level of 0.05</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4682</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and is provided for descriptive purpose only</p_value_desc>
            <method>Student's t-test</method>
            <param_type>Difference in Group Means</param_type>
            <param_value>-216.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-803.6</ci_lower_limit>
            <ci_upper_limit>371.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Predicted FVC</title>
        <description>FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted FVC</title>
          <description>FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>Percent predicted (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.95" spread="18.815"/>
                    <measurement group_id="O2" value="73.95" spread="19.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.04" spread="19.009"/>
                    <measurement group_id="O2" value="74.55" spread="21.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.98" spread="19.324"/>
                    <measurement group_id="O2" value="73.50" spread="20.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.96" spread="19.493"/>
                    <measurement group_id="O2" value="73.91" spread="20.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.56" spread="20.299"/>
                    <measurement group_id="O2" value="72.65" spread="22.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.94" spread="21.000"/>
                    <measurement group_id="O2" value="71.99" spread="21.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.95" spread="20.819"/>
                    <measurement group_id="O2" value="73.55" spread="22.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0383</p_value>
            <method>rank ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0239</p_value>
            <method>rank ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FVC</title>
        <description>FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FVC</title>
          <description>FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>Liter (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.793"/>
                    <measurement group_id="O2" value="2.38" spread="0.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.818"/>
                    <measurement group_id="O2" value="2.37" spread="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.822"/>
                    <measurement group_id="O2" value="2.36" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.820"/>
                    <measurement group_id="O2" value="2.35" spread="0.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.860"/>
                    <measurement group_id="O2" value="2.31" spread="0.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.866"/>
                    <measurement group_id="O2" value="2.30" spread="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.863"/>
                    <measurement group_id="O2" value="2.34" spread="0.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>Student's t-test</method>
            <param_type>Overall Mean Difference</param_type>
            <param_value>95.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.9</ci_lower_limit>
            <ci_upper_limit>154.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0096</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>Student's t-test</method>
            <param_type>Overall Mean Difference</param_type>
            <param_value>84.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>147.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Change in FVC of &gt;5%</title>
        <description>Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Change in FVC of &gt;5%</title>
          <description>Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Analysis in 2019</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Analysis in 2020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Change in FVC of &gt;10%</title>
        <description>Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Change in FVC of &gt;10%</title>
          <description>Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Analysis in 2019</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Analysis in 2020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0114</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0168</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)</title>
        <description>The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)</title>
          <description>The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.19" spread="12.403"/>
                    <measurement group_id="O2" value="49.57" spread="13.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (Primary Analysis in 2019)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="6.193"/>
                    <measurement group_id="O2" value="-0.56" spread="8.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24 (Primary Analysis in 2019)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="7.113"/>
                    <measurement group_id="O2" value="-2.47" spread="8.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (Final Analysis in 2020)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="6.193"/>
                    <measurement group_id="O2" value="-0.89" spread="9.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24 (Final Analysis in 2020)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="7.113"/>
                    <measurement group_id="O2" value="-2.48" spread="8.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0874</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>rank ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1191</p_value>
            <p_value_desc>p-values are not adjusted for multiplicity and are provided for descriptive purpose only.</p_value_desc>
            <method>rank ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6-minute Walk Distance (6MWD)</title>
        <description>Comparison of 6-minute walk distance before beginning and after completing study therapy.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-minute Walk Distance (6MWD)</title>
          <description>Comparison of 6-minute walk distance before beginning and after completing study therapy.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>meter (m)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391.6" spread="114.93"/>
                    <measurement group_id="O2" value="394.0" spread="108.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="66.23"/>
                    <measurement group_id="O2" value="-7.7" spread="57.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="68.11"/>
                    <measurement group_id="O2" value="-26.7" spread="79.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0395</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>rank ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0299</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>rank ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in University of California, San Diego-Shortness of Breath Questionnaire Score</title>
        <description>University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in University of California, San Diego-Shortness of Breath Questionnaire Score</title>
          <description>University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.17" spread="25.204"/>
                    <measurement group_id="O2" value="48.89" spread="23.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="19.707"/>
                    <measurement group_id="O2" value="2.24" spread="18.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" spread="18.701"/>
                    <measurement group_id="O2" value="5.30" spread="22.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7788</p_value>
            <method>rank ANCOVA</method>
            <method_desc>Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.</method_desc>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.00</ci_lower_limit>
            <ci_upper_limit>5.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8289</p_value>
            <p_value_desc>Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate</p_value_desc>
            <method>rank ANCOVA</method>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.00</ci_lower_limit>
            <ci_upper_limit>5.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score in Leicester Cough Questionnaire Score</title>
        <description>The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score in Leicester Cough Questionnaire Score</title>
          <description>The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.13" spread="3.711"/>
                    <measurement group_id="O2" value="15.15" spread="3.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (Primary Analysis in 2019)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="2.903"/>
                    <measurement group_id="O2" value="-0.23" spread="3.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24 (Primary Analysis in 2019)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="2.889"/>
                    <measurement group_id="O2" value="0.04" spread="3.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (Final Analysis in 2020)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="2.903"/>
                    <measurement group_id="O2" value="-0.23" spread="3.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24 (Final Analysis in 2020)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="2.884"/>
                    <measurement group_id="O2" value="0.04" spread="3.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1872</p_value>
            <p_value_desc>p-value was not adjusted for multiplicity and was provided for descriptive purpose only</p_value_desc>
            <method>rank ANCOVA</method>
            <method_desc>Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.</method_desc>
            <param_type>Hodges-Lehmann Median difference</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2019</p_value>
            <p_value_desc>Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate.</p_value_desc>
            <method>rank ANCOVA</method>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cough Visual Analog Scale (VAS) Score</title>
        <description>Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cough Visual Analog Scale (VAS) Score</title>
          <description>Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>millimeter (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.60" spread="27.497"/>
                    <measurement group_id="O2" value="37.18" spread="26.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="20.017"/>
                    <measurement group_id="O2" value="3.32" spread="26.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" spread="26.720"/>
                    <measurement group_id="O2" value="0.78" spread="30.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2995</p_value>
            <method>rank ANCOVA</method>
            <method_desc>Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.</method_desc>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>-2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.00</ci_lower_limit>
            <ci_upper_limit>4.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3372</p_value>
            <p_value_desc>Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate.</p_value_desc>
            <method>rank ANCOVA</method>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>-2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.00</ci_lower_limit>
            <ci_upper_limit>4.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)</title>
        <description>The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)</title>
          <description>The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses. Only participants for whom data were collected are included in the analysis.</population>
          <units>Scores of a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms sub-score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.28" spread="21.687"/>
                    <measurement group_id="O2" value="53.10" spread="21.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Symptoms sub-score at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="19.173"/>
                    <measurement group_id="O2" value="0.86" spread="16.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Symptoms sub-score at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="19.186"/>
                    <measurement group_id="O2" value="-0.66" spread="15.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities sub-score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.93" spread="20.388"/>
                    <measurement group_id="O2" value="66.96" spread="18.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Activities sub-score at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="13.376"/>
                    <measurement group_id="O2" value="1.13" spread="13.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Activities sub-score at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="14.629"/>
                    <measurement group_id="O2" value="2.22" spread="13.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impacts sub-score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.12" spread="20.484"/>
                    <measurement group_id="O2" value="41.47" spread="20.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Impacts sub-score at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="16.826"/>
                    <measurement group_id="O2" value="0.33" spread="13.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Impacts sub-score at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="13.884"/>
                    <measurement group_id="O2" value="1.07" spread="17.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.37" spread="18.465"/>
                    <measurement group_id="O2" value="51.46" spread="17.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Total score at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="13.633"/>
                    <measurement group_id="O2" value="0.53" spread="11.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Total score at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="12.549"/>
                    <measurement group_id="O2" value="0.85" spread="13.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1630</p_value>
            <method>rank ANCOVA</method>
            <method_desc>Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.</method_desc>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>-1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.06</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1851</p_value>
            <p_value_desc>Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate.</p_value_desc>
            <method>rank ANCOVA</method>
            <param_type>Hodges-Lehmann Median Difference</param_type>
            <param_value>-1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.00</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-elective Hospitalization, Both Respiratory and All Cause</title>
        <description>Participants with non-elective hospitalization are reported.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-elective Hospitalization, Both Respiratory and All Cause</title>
          <description>Participants with non-elective hospitalization are reported.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-cause hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory-related hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019. All-cause non-elective hospitalization.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5922</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
            <estimate_desc>Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019. Respiratory non-elective hospitalization.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8057</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
            <estimate_desc>Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020. All-cause non-elective hospitalization.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4613</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
            <estimate_desc>Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020. Respiratory non-elective hospitalization.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9523</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
            <estimate_desc>Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Investigator-reported Acute Exacerbations</title>
        <description>Percentage of participants with acute exacerbation arereported.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Investigator-reported Acute Exacerbations</title>
          <description>Percentage of participants with acute exacerbation arereported.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Investigator-reported Acute Exacerbations</title>
        <description>Time to first investigator reported acute exacerbations from start of treatment are reported.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Investigator-reported Acute Exacerbations</title>
          <description>Time to first investigator reported acute exacerbations from start of treatment are reported.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7871</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>2.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, a &gt;50 m decline of 6MWD, or death.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, a &gt;50 m decline of 6MWD, or death.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.14" lower_limit="24.14" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                    <measurement group_id="O2" value="24.71" lower_limit="24.14" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3660</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4173</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined as the time to the first occurrence of a &gt;10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is defined as the time to the first occurrence of a &gt;10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="24.86" upper_limit="NA">The median was not reached in this analysis, thus an estimate cannot be calculated. In order to calculate the median time at least 50% of participants should report an event and this is not the case in this analysis due to low event number.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="24.14" upper_limit="NA">The median was not reached in this analysis, thus an estimate cannot be calculated. In order to calculate the median time at least 50% of participants should report an event and this is not the case in this analysis due to low event number.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Analysis in 2019</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2726</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Analysis in 2020</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3386</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death From Any Cause</title>
        <description>Time to first documented death from start of treatment is reported.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death From Any Cause</title>
          <description>Time to first documented death from start of treatment is reported.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9969</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>16.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death From Respiratory Diseases</title>
        <description>Time to first documented death due to respiratory diseases from start of treatment will be reported.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death From Respiratory Diseases</title>
          <description>Time to first documented death due to respiratory diseases from start of treatment will be reported.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. The ITT population was the primary analysis population for all efficacy analyses.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The end point could not be analyzed due to the limited number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3231</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank tests based on the time to the first event are to compare the two treatment arms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Baseline (Day 1) to Week 28</time_frame>
        <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period</title>
        <description>Number of participants with dose reduction and treatment interruptions are reported.</description>
        <time_frame>From administration of the first dose of study drug to Week 24</time_frame>
        <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period</title>
          <description>Number of participants with dose reduction and treatment interruptions are reported.</description>
          <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least one dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with at least one dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up</title>
        <description>Number of participants with dose reduction and treatment interruptions are reported.</description>
        <time_frame>From the Follow-up Visit at Week 28 through the follow-up period of 12 Months</time_frame>
        <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment (Pirfenidone)</title>
            <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
          </group>
          <group group_id="O2">
            <title>Open-Label Treatment (Placebo)</title>
            <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up</title>
          <description>Number of participants with dose reduction and treatment interruptions are reported.</description>
          <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least one dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with at least one dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period</title>
        <description>Number of participants withdrawn from trial treatment or trial discontinuations are reported.</description>
        <time_frame>Baseline (Day 1) to Week 24</time_frame>
        <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period</title>
          <description>Number of participants withdrawn from trial treatment or trial discontinuations are reported.</description>
          <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up</title>
        <description>Number of participants withdrawn from trial treatment or trial discontinuations are reported.</description>
        <time_frame>From the Follow-up Visit at Week 28 through the follow-up period of 12 Months</time_frame>
        <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment (Pirfenidone)</title>
            <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
          </group>
          <group group_id="O2">
            <title>Open-Label Treatment (Placebo)</title>
            <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up</title>
          <description>Number of participants withdrawn from trial treatment or trial discontinuations are reported.</description>
          <population>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1) to Week 28 in the double-blind period From the Follow-up Visit at Week 28 through the follow-up period of 12 Months in the open-label treatment period</time_frame>
      <desc>The safety population was defined as all participants with at least one intake of pirfenidone or placebo, i.e., at least one record in the drug-log of the double-blind period with a non-zero dose. Participants in the safety population were assigned to a treatment arm according to the actual treatment they received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pirfenidone</title>
          <description>Participants received pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
        </group>
        <group group_id="E3">
          <title>Open-Label Treatment (Pirfenidone)</title>
          <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
        </group>
        <group group_id="E4">
          <title>Open-Label Treatment (Placebo)</title>
          <description>After participants completed the double-blind treatment period and the follow-up visit at Week 28, they were offered the option to receive open-label pirfenidone within the trial protocol in a safety follow-up period of up to 12 months. A final follow-up visit was performed at the end of the safety period, 28 days after the last open-label dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Lung transplant rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Toxocariasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Varicella zoster pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="127"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="124"/>
                <counts group_id="E3" events="16" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="49" subjects_affected="40" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="94"/>
                <counts group_id="E4" events="39" subjects_affected="30" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" events="25" subjects_affected="18" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="127"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="124"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" events="15" subjects_affected="9" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="127"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="124"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="127"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="124"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

